How Cancer Treatments Affect Diabetes

Cancer therapies do not distinguish between malignant and healthy cells. Several classes of treatment affect glucose metabolism, insulin secretion, and insulin sensitivity through direct cellular damage, induced stress responses, or hormonal manipulation. Understanding these mechanisms allows clinicians to intervene before complications develop.

Chemotherapy and Blood Glucose

Chemotherapeutic agents can provoke hyperglycemia through multiple pathways. The stress response from cytotoxic drugs increases counter‑regulatory hormones such as cortisol and catecholamines, which raise blood glucose. Some drugs, particularly those that accumulate in the pancreas (e.g., L‑asparaginase), can directly impair insulin production. A 2021 meta‑analysis reported that new‑onset hyperglycemia occurs in 15–30 % of patients undergoing chemotherapy for non‑pancreatic cancers (PMCID: PMC8172399). Glucocorticoids often used as premedication further compound the problem, causing transient but marked insulin resistance. Platinum‑based agents (cisplatin, carboplatin) can also induce hyperglycemia by damaging pancreatic beta cells and promoting oxidative stress. A study of cisplatin‑treated lung cancer patients found that mean fasting glucose rose by 18 mg/dL after two cycles, correlating with cumulative cisplatin dose (PMID: 31613345).

The type of chemotherapy regimen matters. For example, FOLFOX and FOLFIRI used in colorectal cancer carry a lower risk of hyperglycemia than platinum‑doublets or high‑dose methotrexate. Alkylating agents such as cyclophosphamide can cause hemorrhagic cystitis and require aggressive hydration, which may dilute insulin and lead to unpredictable glucose levels. Patients with type 1 diabetes on intensive chemotherapy benefit from insulin pump therapy with frequent sensor‑integrated alarms, as the combination of nausea, vomiting, and steroid premedication creates wide glycemic swings.

Radiation Therapy and Pancreatic Function

Radiation directed to the abdomen, especially the pancreatic bed, can destroy beta‑cell mass. The effect is dose‑dependent: doses exceeding 30 Gy to the pancreas significantly reduce insulin secretion capacity. Patients who receive stereotactic body radiation therapy (SBRT) for pancreatic, gastric, or renal tumors face the highest risk. Even moderate doses can lead to permanent, albeit partial, insulin deficiency. After radiation, patients with preexisting diabetes may require a 20–40 % increase in basal insulin or the addition of insulin secretagogues to maintain glycemic targets (Diabetes Spectrum, 2022). Proton beam therapy, though more targeted, can still affect the tail of the pancreas if the treatment field includes the left upper quadrant. A recent retrospective review found that 37 % of patients receiving abdominal radiotherapy developed impaired glucose tolerance within one year, and 12 % progressed to overt diabetes (PMID: 33782540).

Hormone Therapies and Metabolic Effects

Hormonal agents used in breast and prostate cancer can alter glucose homeostasis. Androgen deprivation therapy (ADT) with GnRH agonists reduces lean body mass and increases visceral adiposity, worsening insulin resistance. A study of men with prostate cancer found that ADT raised fasting glucose by an average of 15 mg/dL within six months. Similarly, aromatase inhibitors in breast cancer can disrupt estrogen‑mediated glucose disposal, leading to higher postprandial glucose levels. Patients on adjuvant endocrine therapy should have fasting glucose and HbA1c measured quarterly during the first year. The combination of ADT with radiation therapy also increases the risk of metabolic syndrome; a prospective cohort reported a 50 % higher incidence of new‑onset diabetes in men receiving ADT compared to those on active surveillance (NEJM, 2016).

Immunotherapy and Autoimmune Interactions

Immune checkpoint inhibitors (ICIs) such as anti‑PD‑1 and anti‑CTLA‑4 antibodies can trigger autoimmune diabetes in susceptible individuals. This presents as acute, often fulminant, type 1 diabetes with severe hyperglycemia and ketoacidosis. The incidence is approximately 1–2 % of ICI recipients, but it may be higher in those with anti‑GAD antibodies. For patients with established type 1 diabetes, ICIs can worsen glycemic stability because the induced inflammation amplifies insulin resistance. Management requires rapid‑acting insulin protocols and close collaboration with an endocrinologist before each cycle (National Cancer Institute, 2023). Emerging evidence suggests that patients who develop ICI‑induced diabetes often have lower baseline C‑peptide levels and may harbor genetic risk variants (HLA‑DR4). Proactive monitoring of blood glucose and autoantibodies (GAD65, IA‑2) before starting ICIs and at each cycle can identify at‑risk individuals, allowing early intervention with basal‑bolus insulin regimens.

Targeted Therapies and Metabolic Disruption

Kinase inhibitors, especially those targeting VEGF receptors and mTOR, produce metabolic effects that complicate diabetes control. Sunitinib and sorafenib can cause hypothyroidism, which slows metabolism and alters insulin clearance. Everolimus, an mTOR inhibitor, frequently causes hyperglycemia (grade 3‑4 in up to 15 % of patients) by disrupting insulin signaling in skeletal muscle. Tyrosine kinase inhibitors (TKIs) used in chronic myeloid leukemia have been associated with both hyperglycemia and, paradoxically, hypoglycemia through off‑target effects on glucose transporters. Patients on TKIs need frequent glucose monitoring and may require dose adjustments of both antidiabetic medications and the TKI itself. For example, nilotinib can induce hyperglycemia in up to 30 % of patients, while imatinib has been reported to improve glycemic control in some cases (PMID: 28714475). A practical approach is to obtain a baseline HbA1c and fasting glucose before initiating any kinase inhibitor, then recheck after two weeks and monthly thereafter until stable.

Long‑Term Implications for Diabetes Management

Survivors of cancer are at increased risk for long‑term metabolic derangements, even after treatment ends. These cumulative effects place added strain on the cardiovascular system and kidneys, requiring vigilant management.

Cardiovascular Risk

Cancer treatments accelerate atherosclerosis independently of diabetes. Anthracyclines and radiation to the chest damage the myocardium; when combined with diabetes‑related microvascular disease, the net effect is a markedly elevated risk of heart failure and coronary artery disease. Survivorship guidelines recommend annual lipid panels, blood pressure checks, and, for many patients, a stress echocardiogram five years after chest irradiation. Diabetes medications with cardioprotective properties, such as SGLT2 inhibitors and GLP‑1 receptor agonists, are strongly preferred for these individuals. A recent consensus statement from the American Heart Association advises starting an SGLT2 inhibitor in cancer survivors with diabetes and established cardiovascular disease or high risk, even if HbA1c is near target (Circulation, 2022).

Nephropathy and Renal Considerations

Platinum‑based chemotherapies (cisplatin, carboplatin) and certain TKIs can cause chronic kidney disease, compounding the nephropathy common in long‑standing diabetes. Reduced renal function affects the clearance of both insulin and many oral antidiabetic agents. Metformin is contraindicated when eGFR falls below 30 mL/min/1.73 m², and sulfonylureas carry a risk of prolonged hypoglycemia in renal impairment. The oncology team must provide accurate, ongoing creatinine clearance estimates so that the diabetes care plan can be adjusted accordingly. For patients with eGFR between 30–45 mL/min, dose reductions of insulin and careful monitoring are essential. Some SGLT2 inhibitors retain efficacy down to eGFR of 25 mL/min, but their glucose‑lowering effect diminishes; they are still beneficial for heart and kidney protection at lower filtration rates (PMID: 34763559).

Neuropathy and Medication Adjustments

Peripheral neuropathy from taxanes, platinum agents, or bortezomib can mimic or worsen diabetic neuropathy. This makes it difficult to rely on neuropathic symptoms for early detection of hypoglycemia. Patients with combined chemotherapy‑induced and diabetes‑related neuropathy lose protective sensation in their feet, increasing the risk of ulcerations. They also may not feel classic sympathetic warnings of low blood glucose. Structured education on hypoglycemia unawareness and the use of continuous glucose monitors (CGMs) with alarms are essential. Annual comprehensive foot exams should include monofilament testing and vascular assessment, with referrals to podiatry for callus debridement or custom orthotics. A multidisciplinary wound care team can prevent amputations in this high‑risk population.

Osteoporosis and Fracture Risk

Diabetes itself is associated with increased fracture risk, and many cancer treatments worsen bone health. Aromatase inhibitors, ADT, and chronic glucocorticoid use accelerate bone loss. Survivors with type 2 diabetes often have higher bone mineral density but paradoxically weaker bone microarchitecture. Baseline dual‑energy X‑ray absorptiometry (DXA) scans should be obtained within one year of starting endocrine therapy. Calcium and vitamin D supplementation, weight‑bearing exercise, and, when indicated, bisphosphonates or denosumab are necessary to prevent fragility fractures (JCEM, 2019). For patients on ADT, testosterone therapy is contraindicated, so bone‑protective agents become the primary strategy.

Managing Diabetes During Active Cancer Treatment

Coordinating diabetes care amid frequent hospital visits, nausea, appetite changes, and varying steroid doses demands a flexible, multidisciplinary approach.

Multidisciplinary Care Coordination

Ideally, a nurse navigator or diabetes care and education specialist (DCES) serves as the link between oncology and endocrinology. Before each new treatment cycle, the DCES reviews the medication list, steroid dosage, and recent blood glucose trends. A shared electronic health record (EHR) allows real‑time updates. Weekly huddles between the rounding oncologist, pharmacist, and diabetes team are associated with 30 % fewer hyperglycemic episodes during inpatient chemotherapy (AJMC, 2020). Standardized order sets for insulin therapy, including weight‑based basal‑bolus calculators and correctional scales for high‑dose steroids, reduce variability. When initiating a new cancer drug known to affect glucose, the oncology pharmacist can alert the diabetes team to schedule a pre‑cycle visit.

Medication Adjustments

Oral agents that depend on renal or hepatic function may become unsafe during chemotherapy. Metformin should be temporarily held during acute kidney injury, severe vomiting, or contrast studies. Sulfonylureas are often deprioritized due to irregular meal patterns. Insulin therapy is the most flexible option: prandial insulin can be withheld if appetite is poor, and correctional sliding scales can handle steroid‑induced hyperglycemia. For inpatients, basal‑bolus regimens with a scheduled neutral protamine Hagedorn (NPH) dose to cover morning steroid pulses provide superior control compared with sliding scales alone. Newer ultra‑long‑acting insulins (degludec, insulin glargine U300) offer less day‑to‑day variability, which is beneficial during the fluctuating caloric intake of cancer treatment. For patients receiving enteral or parenteral nutrition, a dedicated insulin protocol with regular blood glucose monitoring every four hours is mandatory to prevent severe hyper‑ or hypoglycemia.

Nutritional Strategies

Cancer‑related cachexia or anorexia often conflicts with diabetes dietary restrictions. The priority during active treatment is to maintain caloric intake and prevent weight loss. The diabetes diet should be liberalized: patients are encouraged to eat whatever they can tolerate, with insulin matching carbohydrate intake. A registered dietitian experienced in oncology can advise on low‑glycemic high‑calorie options (e.g., avocado smoothies, nut butters) that stabilize blood glucose without causing hypoglycemic lows. Tube feeding or parenteral nutrition, when needed, requires a separate insulin protocol involving continuous insulin infusion or split‑dose NPH. Adding a liquid nutritional supplement such as Ensure Glucerna to the diet can provide balanced macronutrients while minimizing postprandial spikes. The dietitian should also address taste changes, mucositis, and constipation, which are common side effects that affect dietary adherence.

Physical Activity and Fatigue

Cancer‑related fatigue limits exercise capacity, but even light physical activity improves insulin sensitivity and reduces the need for high insulin doses. Short (10‑minute) bouts of walking after meals, resistance band exercises, or gentle yoga are feasible for most patients. The oncology physical therapist should collaborate with the diabetes educator to produce a safe, individualized routine that avoids injury in those with thrombocytopenia or neuropathy. For survivors with ostomies, central lines, or lymphedema, certain exercises require modifications. Pre‑ and post‑exercise blood glucose checks help fine‑tune insulin dosing and carbohydrate intake. A structured exercise program also combats the loss of lean body mass induced by ADT and steroid therapy.

Monitoring and Technology

Frequent self‑monitoring of blood glucose (SMBG) remains the standard, but CGMs offer distinct advantages during cancer care. They alert patients to rapid glucose excursions caused by steroid bursts or missed meals and reduce the burden of finger sticks during neutropenic periods. Some patients experience CGM accuracy issues due to peripheral edema or dehydration; confirmatory SMBG is recommended when readings do not match symptoms. Insulin pumps with predictive low‑glucose suspend features can be used safely, provided the patient has adequate support from a diabetes specialist aware of the cancer treatment schedule. Hybrid closed‑loop systems (artificial pancreas) are now being studied in the oncology setting; early data show improved time‑in‑range without increasing hypoglycemia (PMID: 34904415). For patients undergoing chemotherapy that causes severe thrombocytopenia, CGMs reduce the risk of bleeding from repetitive finger sticks.

Perioperative Considerations for Cancer Surgery

Many cancer patients require surgery (tumor resection, port placement, ostomy creation). Perioperative hyperglycemia is associated with increased infections, delayed wound healing, and longer hospital stays. For elective procedures, HbA1c should be below 8 % (ideally <7.5 %). On the day of surgery, basal insulin is continued (often at 80 % of usual dose), and short‑acting insulin is held until oral intake resumes. An intraoperative insulin infusion protocol is recommended for procedures lasting more than two hours. Post‑operatively, a basal‑bolus regimen with scheduled correctional insulin should be initiated immediately, even if the patient is NPO, to prevent stress hyperglycemia. Collaboration between the surgical oncologist, anesthesiologist, and endocrinologist ensures a safe transition through the perioperative period.

Post‑Treatment Diabetes Care

After active cancer treatment concludes, diabetes management often requires reassessment. The patient’s physiology has changed, and the focus shifts from acute control to long‑term prevention of diabetic complications.

Survivorship Planning

A survivorship care plan (SCP) issued by the oncology team should summarize the treatments received, their likely late effects, and a schedule for diabetes‑related follow‑up. The SCP should specify the cumulative dose of cardiotoxic agents, radiation fields, and any agents that permanently impaired pancreatic function. The primary care physician or endocrinologist uses this document to set surveillance intervals for retinopathy, nephropathy, and cardiovascular disease. In addition to annual dilated eye exams and urine albumin‑to‑creatinine ratio, survivors who received chest radiation should have a baseline cardiac MRI or stress echocardiogram within five years of completion. Diabetes‑related education should include information about the late effects of treatment and how they might alter medication needs over time.

Reassessment of Diabetes Goals

HbA1c targets may need to be relaxed for patients with limited life expectancy from advanced or metastatic cancer. The American Diabetes Association recommends individualizing glycemic goals: an HbA1c below 7 % is appropriate for most otherwise healthy survivors, but 7.5–8.5 % may be safer for older adults with multiple comorbidities or those prone to severe hypoglycemia. Regular shared decision‑making between the patient, oncologist, and endocrinologist ensures that goals align with the overall prognosis and quality of life. For patients on palliative systemic therapy, the emphasis should shift to avoiding symptomatic hyperglycemia and hypoglycemia rather than achieving a tight number. Frequent CGM use with low‑ and high‑glucose alerts can help maintain comfort and reduce emergency room visits.

Psychological Support and Coping

Survivors often face diabetes distress superimposed on cancer‑related anxiety. The burden of managing two chronic diseases can lead to burnout, missed medication doses, and avoidance of follow‑up appointments. Cognitive behavioral therapy (CBT) and peer support groups tailored to cancer survivors with diabetes have shown improvements in self‑care behaviors and HbA1c. Screening for depression using the PHQ‑9 should be part of every six‑month survivorship visit. Diabetes technology, such as automated insulin delivery systems, can reduce the mental load of constant decision‑making. Oncology social workers should be integrated into the survivorship clinic to address financial toxicity from dual medication costs and copays for CGMs and pumps.

Emerging Research and Future Directions

Several promising avenues may reduce the metabolic toll of cancer treatments. Preclinical studies are exploring beta‑cell protective agents to co‑administer with chemotherapy. Clinical trials are evaluating metformin as an adjunct to reduce cancer recurrence risk in patients with diabetes, potentially offering a dual benefit. For example, the ongoing MA‑32 trial randomizes early‑stage breast cancer patients with diabetes to metformin versus placebo and is examining both glycemic control and invasive disease‑free survival (NCT02970565). Immunotherapy‑associated diabetes is being investigated with checkpoint inhibitor combinations that preserve beta‑cell function, such as co‑treatment with IL‑2 receptor antagonists. Finally, artificial pancreas systems adapted for the variable insulin needs of cancer patients are in early feasibility studies. A pilot trial of the MiniMed 780G system in patients receiving high‑dose glucocorticoids showed that automated mode maintained time‑in‑range above 70 % despite wide glucose variability (PMID: 36136952). As cancer survival rates continue to rise, the intersection of oncology and endocrinology will become an increasingly vital field of research and clinical practice.

Conclusion

Cancer treatments affect long‑term diabetes management through direct pancreatic damage, hormonal changes, metabolic disruption, and late effects on the heart, kidneys, and nerves. Successful management requires a coordinated care team, flexible medication strategies during active therapy, and thoughtful reassessment after treatment ends. Patients who receive comprehensive, personalized diabetes care during their cancer journey can maintain stable glycemic control, reduce the risk of complications, and achieve better overall health outcomes in survivorship. Clinicians must remain vigilant to the unique interplay between cancer therapeutics and glucose metabolism, adapting guidelines to each patient’s changing physiology and priorities.